The Critical Role of Inflammation in the Pathogenesis and Progression of Myeloid Malignancies
Open accessThe DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Abstract
Hematopoietic stem cells (HSCs) maintain an organism’s immune system for a lifetime, and derangements in HSC proliferation and differentiation result in hematologic malignancies. Chronic inflammation plays a contributory if not causal role in HSC dysfunction. Inflammation induces HSC exhaustion, which promotes the emergence of mutant clones that may be resistant to an inflammatory microenvironment; this likely promotes the onset of a myeloid hematologic malignancy. Inflammatory cytokines are characteristically high in patients with myeloid malignancies and are linked to disease initiation, symptom burden, disease progression, and worsened prognostic survival. This review will cover our current understanding of the role of inflammation in the initiation, progression, and complications of myeloid hematologic malignancies, drawing from clinical studies as well as murine models. We will also highlight inflammation as a therapeutic target in hematologic malignancies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The gut microbiota shapes intestinal immune responses during health and disease
Round, J. L., & Mazmanian, S. K. (2009) · Nature Reviews Immunology · doi:10.1038/nri2515 · Cited by 5,029
Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders
Baxter, E. J., Scott, L. M., Campbell, P. J., East, C., Fourouclas, N., Swanton, S., Vassiliou, G. S., Bench, A. J., Boyd, E. M., Curtin, N., et al. (2005) · The Lancet · doi:10.1016/s0140-6736(05)71142-9 · Cited by 3,548
Clonal hematopoiesis and risk of atherosclerotic cardiovascular disease
Jaiswal, S., Natarajan, P., Silver, A. J., Gibson, C. J., Bick, A. G., Shvartz, E., McConkey, M., Gupta, N., Gabriel, S., Ardissino, D., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1701719 · Cited by 2,683
Genome-wide association defines more than 30 distinct susceptibility loci for Crohn's disease
the NIDDK IBD Genetics Consortium, Barrett, J. C., the Belgian-French IBD Consortium, the Wellcome Trust Case Control Consortium, Hansoul, S., Nicolae, D. L., Cho, J. H., Duerr, R. H., Rioux, J. D., Brant, S. R., et al. (2008) · Nature Genetics · doi:10.1038/ng.175 · Cited by 2,593
A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis
Verstovsek, S., Mesa, R. A., Gotlib, J., Levy, R. S., Gupta, V., DiPersio, J. F., Catalano, J. V., Deininger, M., Miller, C., Silver, R. T., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1110557 · Cited by 2,103 · cited 1×
“These tools were also used to objectively measure the impact of the JAK1/2-inhibitor, ruxolitinib, on symptom burden in the COMFORT-I trial [46].”
MethodThe role of gut microbiota in immune homeostasis and autoimmunity
Wu, H.-J., & Wu, E. (2012) · Gut Microbes · doi:10.4161/gmic.19320 · Cited by 1,426
Tet2 loss leads to increased hematopoietic stem cell self-renewal and myeloid transformation
Moran-Crusio, K., Reavie, L., Shih, A., Abdel-Wahab, O., Ndiaye-Lobry, D., Lobry, C., Figueroa, M. E., Vasanthakumar, A., Patel, J., Zhao, X., et al. (2011) · Cancer Cell · doi:10.1016/j.ccr.2011.06.001 · Cited by 1,339 · cited 2×
“As a result, HSCs with mutations that skew towards self-renewal, such as Tet2 or DNMT3A, will have a selective advantage over aged HSCs [84,86].”
BackgroundGenome-wide association study identifies eight loci associated with blood pressure
Wellcome Trust Case Control Consortium, Newton-Cheh, C., Johnson, T., Gateva, V., Tobin, M. D., Bochud, M., Coin, L., Najjar, S. S., Zhao, J. H., Heath, S. C., et al. (2009) · Nature Genetics · doi:10.1038/ng.361 · Cited by 1,215
Banerjee, S., Biehl, A., Gadina, M., Hasni, S., & Schwartz, D. M. (2017) · Drugs · doi:10.1007/s40265-017-0701-9 · Cited by 1,206 · cited 1×
“The efficacy of JAK inhibitors is currently being investigated on solid tumors such as pancreatic, lung, colon and breast cancers [59] as well as inflammatory bowel diseases [60,61].”
BackgroundBone progenitor dysfunction induces myelodysplasia and secondary leukaemia
Raaijmakers, M. H. G. P., Mukherjee, S., Guo, S., Zhang, S., Kobayashi, T., Schoonmaker, J. A., Ebert, B. L., Al-Shahrour, F., Hasserjian, R. P., Scadden, E. O., et al. (2010) · Nature · doi:10.1038/nature08851 · Cited by 1,115
Human bone marrow hematopoietic stem cells are increased in frequency and myeloid-biased with age
Pang, W. W., Price, E. A., Sahoo, D., Beerman, I., Maloney, W. J., Rossi, D. J., Schrier, S. L., & Weissman, I. L. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1116110108 · Cited by 991 · cited 1×
“During aging, human and mouse HSCs increase in frequency but have inferior self-renewal capabilities [69,70].”
BackgroundCoombs, C. C., Zehir, A., Devlin, S. M., Kishtagari, A., Syed, A., Jonsson, P., Hyman, D. M., Solit, D. B., Robson, M. E., Baselga, J., et al. (2017) · Cell stem cell · doi:10.1016/j.stem.2017.07.010 · Cited by 866
Age-Associated Characteristics of Murine Hematopoietic Stem Cells
Sudo, K., Ema, H., Morita, Y., & Nakauchi, H. (2000) · The Journal of Experimental Medicine · doi:10.1084/jem.192.9.1273 · Cited by 722 · cited 1×
“Aged HSCs also display myeloid skewed differentiation with a decline in lymphopoiesis [71,72].”
BackgroundJAK/STAT signaling in hematological malignancies
Vainchenker, W., & Constantinescu, S. N. (2013) · Oncogene · doi:10.1038/onc.2012.347 · Cited by 528
Beerman, I., Bock, C., Garrison, B. S., Smith, Z. D., Gu, H., Meissner, A., & Rossi, D. J. (2013) · Cell Stem Cell · doi:10.1016/j.stem.2013.01.017 · Cited by 485
Inflamm-aging of hematopoiesis, hematopoietic stem cells, and the bone marrow microenvironment
Kovtonyuk, L. V., Fritsch, K., Feng, X., Manz, M. G., & Takizawa, H. (2016) · Frontiers in Immunology · doi:10.3389/fimmu.2016.00502 · Cited by 371 · cited 1×
“In steady state, HSCs are mostly quiescent but in response to hematopoietic challenges such as blood loss, infection, or inflammation, HSCs exit from quiescence to proliferate and increase the output of mature hematopoietic cells [74].”
BackgroundAntibiotics impair murine hematopoiesis by depleting the intestinal microbiota
Josefsdottir, K. S., Baldridge, M. T., Kadmon, C. S., & King, K. Y. (2017) · Blood · doi:10.1182/blood-2016-03-708594 · Cited by 343
Gillis, N. K., Ball, M., Zhang, Q., Ma, Z., Zhao, Y., Yoder, S. J., Balasis, M. E., Mesa, T. E., Sallman, D. A., Lancet, J. E., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30627-1 · Cited by 317 · cited 1×
“Clonal hematopoiesis can be found in over 10% of the population over the age of 70, and increases in prevalence with age [68].”
BackgroundHarrison, D. E., & Astle, C. M. (1982) · The Journal of Experimental Medicine · doi:10.1084/jem.156.6.1767 · Cited by 281
Hinds, D. A., Barnholt, K. E., Mesa, R. A., Kiefer, A. K., Do, C. B., Eriksson, N., Mountain, J. L., Francke, U., Tung, J. Y., Nguyen, H. (., et al. (2016) · Blood · doi:10.1182/blood-2015-06-652941 · Cited by 267 · cited 1×
“Moreover, SNPs in SH2B3 (Lnk) are associated with MPN [17], multiple sclerosis and atherosclerosis [23], though atherosclerosis is not an autoimmune disease but a chronic inflammatory state.”
BackgroundChronic Infection Depletes Hematopoietic Stem Cells through Stress-Induced Terminal Differentiation
Matatall, K. A., Jeong, M., Chen, S., Sun, D., Chen, F., Mo, Q., Kimmel, M., & King, K. Y. (2016) · Cell Reports · doi:10.1016/j.celrep.2016.11.031 · Cited by 262
Risks of myeloid malignancies in patients with autoimmune conditions
Anderson, L. A., Pfeiffer, R. M., Landgren, O., Gadalla, S., Berndt, S. I., & Engels, E. A. (2009) · British Journal of Cancer · doi:10.1038/sj.bjc.6604935 · Cited by 253 · cited 2×
“Specifically, AML was most closely associated with systemic lupus erythematosus, rheumatoid arthritis, polymyalgia rheumatica, and autoimmune hemolytic anemia while MDS was associated with pernicious anemia and rheumatoid arthritis [12].”
BackgroundThe microbiota in inflammatory bowel disease: Current and therapeutic insights
Lane, E. R., Zisman, T., & Suskind, D. (2017) · Journal of Inflammation Research · doi:10.2147/jir.s116088 · Cited by 226 · cited 1×
“Microbiota dysregulation (or dysbiosis) is seen in a variety of inflammatory diseases including inflammatory bowel disease [107], lupus [108] and rheumatoid arthritis [109].”
BackgroundVaidya, R., Gangat, N., Jimma, T., Finke, C. M., Lasho, T. L., Pardanani, A., & Tefferi, A. (2012) · American Journal of Hematology · doi:10.1002/ajh.23295 · Cited by 149
Cytokine profiles in polycythemia vera and essential thrombocythemia patients: Clinical implications
Pourcelot, E., Trocme, C., Mondet, J., Bailly, S., Toussaint, B., & Mossuz, P. (2014) · Experimental Hematology · doi:10.1016/j.exphem.2014.01.006 · Cited by 132 · cited 4×
“The impact of chronic inflammation on disease burden is particularly obvious in chronic MPNs which include polycythemia vera (PV), essential thrombocythemia (ET), and primary myelofibrosis (PMF).”
BackgroundInfluentialSporadic colorectal cancer: microbial contributors to disease prevention, development and therapy
Drewes, J. L., Housseau, F., & Sears, C. L. (2016) · British Journal of Cancer · doi:10.1038/bjc.2016.189 · Cited by 121
Li, S., Chen, L., Jin, W., Ma, X., Ma, Y., Dong, F., Zhu, H., Li, J., & Wang, K. (2017) · Scientific Reports · doi:10.1038/s41598-017-18278-x · Cited by 68 · cited 10×
“In aggressive hematologic malignancies such as AML, the major focus is on eradication of the leukemic clone because the consequence of not targeting the mutant clone is fatal.”
ResultInfluentialSurapaneni, P., & Scherber, R. M. (2019) · Current Hematologic Malignancy Reports · doi:10.1007/s11899-019-00516-w · Cited by 10
Self-citation
Cited by
γδ T cells: origin and fate, subsets, diseases and immunotherapy
Hu, Y., Hu, Q., Li, Y., Lu, L., Xiang, Z., Yin, Z., Kabelitz, D., & Wu, Y. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01653-8 · Cited by 382
Inflammation-Induced Tumorigenesis and Metastasis
Hibino, S., Kawazoe, T., Kasahara, H., Itoh, S., Ishimoto, T., Sakata-Yanagimoto, M., & Taniguchi, K. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22115421 · Cited by 290
Caiado, F., Pietras, E. M., & Manz, M. G. (2021) · Journal of Experimental Medicine · doi:10.1084/jem.20201541 · Cited by 289
Inflammatory Pathophysiology as a Contributor to Myeloproliferative Neoplasms
Fisher, D. A. C., Fowles, J. S., Zhou, A., & Oh, S. T. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.683401 · Cited by 115
Surapaneni, P., & Scherber, R. M. (2019) · Current Hematologic Malignancy Reports · doi:10.1007/s11899-019-00516-w · Cited by 10
Self-citation
Metadata
- Authors
- Craver, B., El Alaoui, K., Scherber, R., & Fleischman, A.
- Venue
- Cancers
- Publisher
- MDPI AG
- Published
- 2018-04-03
- Volume
- 10
- Issue
- 4
- Pages
- 104
- ISSN
- 2072-6694 (ISSN-L)
- OpenAlex
- W2796018590
- Cited by
- 116
- References
- 28
- FWCI
- 6.84
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.